



Supplementary Figure 1 | **US venture capital investment in infectious disease vaccine companies.** Investments reported by the Biotechnology Innovation Organization (BIO) were fairly flat over the period 2008–2014, with an average of \$65 million per year. Two companies raised large rounds of capital in 2015 (PaxVax) and 2016 (Moderna). Investments in other companies in 2016–2017 were below the 2008–2015 average. Source: Thomas & Wessel, Emerging Therapeutic Company Investment and Deal Trends, BIO Industry Analysis, June 2017.

Supplementary Table 1 | **Selected vaccine candidates in phase III development**

Candidate	Sponsor	Target
PF-06425090	Pfizer	<i>Clostridium difficile</i>
TAK-003	Takeda	Dengue
DTP–IPV–Hib vaccine (Japan)	Sanofi Pasteur	DTP–IPV–Hib
MVA–BN Filo monovalent	Janssen/Bavarian Nordic	Ebola
Ad26.ZEBOV	Janssen	Ebola
V920	Merck & Co./NewLink Genetics	Ebola
Hepatitis A vaccine	PaxVax	Hepatitis A
Sci-B-Vac	VBI Vaccines	Hepatitis B
V212	Merck & Co.	Herpes zoster
H5N1 vaccine	Seqirus	Pandemic influenza
VLP QIV	Medicago	Seasonal influenza
Fluzone QIV HD	Sanofi Pasteur	Seasonal influenza
Seqirus QIV	Seqirus	Seasonal influenza
GSK209762	GlaxoSmithKline	Measles, mumps and rubella
Men Quad TT	Sanofi Pasteur	Meningococcal
RSV F protein vaccine	Novavax	RSV
Imvamune	Bavarian Nordic	Smallpox

Data are from 28 February 2018. HD, high-dose; QIV, quadrivalent vaccine; RSV, respiratory syncytial virus.